Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide
Cells · 02.10.2023 · 12 (19) · 2395
DOI: 10.3390/cells12192395 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 02.10.2023. Verfasst von Umme Sabrina Haque und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuroscience, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada. Hauptthemen laut MEDLINE: Cell-Penetrating Peptides, Muscular Dystrophy, Duchenne, Muscular Atrophy, Spinal. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 152 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR.
Abstract (Originalsprache)
Antisense oligonucleotide-based (ASO) therapeutics have emerged as a promising strategy for the treatment of human disorders. Charge-neutral PMOs have promising biological and pharmacological properties for antisense applications. Despite their great potential, the efficient delivery of these therapeutic agents to target cells remains a major obstacle to their widespread use. Cellular uptake of naked PMO is poor. Cell-penetrating peptides (CPPs) appear as a possibility to increase the cellular uptake and intracellular delivery of oligonucleotide-based drugs. Among these, the DG9 peptide has been identified as a versatile CPP with remarkable potential for enhancing the delivery of ASO-based therapeutics due to its unique structural features. Notably, in the context of phosphorodiamidate morpholino oligomers (PMOs), DG9 has shown promise in enhancing delivery while maintaining a favorable toxicity profile. A few studies have highlighted the potential of DG9-conjugated PMOs in DMD (Duchenne Muscular Dystrophy) and SMA (Spinal Muscular Atrophy), displaying significant exon skipping/inclusion and functional improvements in animal models. The article provides an overview of a detailed understanding of the challenges that ASOs face prior to reaching their targets and continued advances in methods to improve their delivery to target sites and cellular uptake, focusing on DG9, which aims to harness ASOs’ full potential in precision medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neuroscience, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
- Department of Medical Genetics, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2H7, Canada.
- The Friends of Garrett Cumming Research & Muscular Dystrophy Canada HM Toupin Neurological Science Research, Edmonton, AB T6G 2H7, Canada.
ORCID-Profile: Toshifumi Yokota
Förderung
- CIHR
Zitieren
APA
Haque, U. S., & Yokota, T. (2023). Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide. Cells, 12(19), 2395. https://doi.org/10.3390/cells12192395
Vancouver
Haque US, Yokota T. Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide. Cells. 2023;12(19):2395. doi:10.3390/cells12192395
BibTeX
@article{Haque2023,
author = {Haque, Umme Sabrina and Yokota, Toshifumi},
title = {Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide},
journal = {Cells},
year = {2023},
volume = {12},
number = {19},
pages = {2395},
doi = {10.3390/cells12192395}
}
EUVIMED